Novartis AG ADR (NVS)vsTeck Resources Ltd Class B (TECK)
NVS
Novartis AG ADR
$150.75
+1.44%
HEALTHCARE · Cap: $286.27B
TECK
Teck Resources Ltd Class B
$50.36
+3.71%
BASIC MATERIALS · Cap: $23.82B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 427% more annual revenue ($56.67B vs $10.76B). NVS leads profitability with a 24.7% profit margin vs 13.0%. TECK appears more attractively valued with a PEG of 0.96. TECK earns a higher WallStSmart Score of 73/100 (B).
NVS
Buy51
out of 100
Grade: C-
TECK
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-243.7%
Fair Value
$48.62
Current Price
$150.75
$102.13 premium
Margin of Safety
+37.4%
Fair Value
$96.41
Current Price
$50.36
$46.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Keeps 25 of every $100 in revenue as profit
Strong operational efficiency at 27.8%
Generating 1.6B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 32.6%
Growing faster than its price suggests
Earnings expanding 42.5% YoY
Areas to Watch
2.2% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Earnings declined 11.6%
Grey zone — moderate risk
ROE of 4.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 24.7% and operating margin at 27.8%.
Bull Case : TECK
The strongest argument for TECK centers on Price/Book, Operating Margin, PEG Ratio. PEG of 0.96 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, PEG Ratio.
Bear Case : TECK
The primary concerns for TECK are Altman Z-Score, Return on Equity.
Key Dynamics to Monitor
TECK carries more volatility with a beta of 1.53 — expect wider price swings.
TECK is growing revenue faster at 9.8% — sustainability is the question.
NVS generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
TECK scores higher overall (73/100 vs 51/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Teck Resources Ltd Class B
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Teck Resources Limited is dedicated to exploring, acquiring, developing and producing natural resources in Asia, Europe and North America. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?